Vestergaard, Hanne

Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay

Kristensen, T., Vestergaard, H., & Møller, M. B. (2011) · The Journal of Molecular Diagnostics

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 208

Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations

Broesby‐Olsen, S., Vestergaard, H., Mortz, C. G., Jensen, B., Havelund, T., Hermann, A. P., Siebenhaar, F., Møller, M. B., Kristensen, T. K., Bindslev‐Jensen, C., et al. (2018) · Allergy

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 112

Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood

Broesby-Olsen, S., Oropeza, A. R., Bindslev-Jensen, C., Vestergaard, H., Møller, M. B., Siebenhaar, F., Kristensen, T., & Mortz, C. G. (2015) · Journal of Allergy and Clinical Immunology

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 54

Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis

Kristensen, T., Vestergaard, H., Bindslev‐Jensen, C., Mortz, C. G., Kjaer, H. F., Ollert, M., Møller, M. B., Broesby‐Olsen, S., & the Mastocytosis Centre Odense University Hospital (MastOUH) (2017) · Allergy

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 38

Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000–2016

Hansen, A.-B. E., Vestergaard, H., Dessau, R. B., Bodilsen, J., Andersen, N. S., Omland, L. H., Christiansen, C. B., Ellermann-Eriksen, S., Nielsen, L., Benfield, T., et al. (2020) · Clinical Epidemiology

Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus research

Cited by 27

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, F., Mahon, F.-X., Richter, J., Piciocchi, A., Cipriani, M., Nicolini, F. E., Mayer, J., Zackova, D., Janssen, J. J. W. M., Panayiotidis, P., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsCancer survivorship and care

Cited by 15